Skip to content
10-Q

Quarterly Report

SOLENO THERAPEUTICS INC

0001193125-26-212205

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 52.12M sh
Shares Diluted Q1 2026 · Mar 31, 2026 53.07M sh
Shares Diluted Q1 2026 · Mar 31, 2025 46.18M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $4K
Stock Repurchased Q1 2026 · Mar 31, 2025 $0
Capex Q1 2026 · Mar 31, 2026 $40K
Capex Q1 2026 · Mar 31, 2025 $5K
Operating Cash Flow Q1 2026 · Mar 31, 2026 $25.98M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$32.75M
Long Term Debt Q1 2026 · Mar 31, 2026 $49.87M
Long Term Debt Q1 2026 · Dec 31, 2025 $49.86M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $133.03M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $70.11M
Stockholders Equity Q1 2026 · Mar 31, 2026 $495.8M
Stockholders Equity Q1 2026 · Dec 31, 2025 $450.12M
Stockholders Equity Q1 2026 · Mar 31, 2025 $232.26M
Stockholders Equity Q1 2026 · Dec 31, 2024 $245.11M
Current Liabilities Q1 2026 · Mar 31, 2026 $58.05M
Current Liabilities Q1 2026 · Dec 31, 2025 $61.36M
Total Liabilities Q1 2026 · Mar 31, 2026 $112.59M
Total Liabilities Q1 2026 · Dec 31, 2025 $113.72M
Current Assets Q1 2026 · Mar 31, 2026 $326.38M
Current Assets Q1 2026 · Dec 31, 2025 $355.81M
Total Assets Q1 2026 · Mar 31, 2026 $608.39M
Total Assets Q1 2026 · Dec 31, 2025 $563.83M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.59
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.95
Eps Basic Q1 2026 · Mar 31, 2026 $0.60
Eps Basic Q1 2026 · Mar 31, 2025 −$0.95
Sga Expense Q1 2026 · Mar 31, 2026 $50.37M
Sga Expense Q1 2026 · Mar 31, 2025 $29.26M
Rd Expense Q1 2026 · Mar 31, 2026 $11.27M
Rd Expense Q1 2026 · Mar 31, 2025 $13.52M
Net Income Q1 2026 · Mar 31, 2026 $31.38M
Net Income Q1 2026 · Mar 31, 2025 −$43.77M
Operating Income Q1 2026 · Mar 31, 2026 $31.28M
Operating Income Q1 2026 · Mar 31, 2025 −$45.74M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $1.2M